Innoviva, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Burlingame, CA, May 4, 2026 — Innoviva, Inc. (NASDAQ: INVA), a pharmaceutical company listed on the NASDAQ Global Select Market, has released the results of its 2026 Annual Meeting of Stockholders. The meeting, held on May 4, 2026, included several significant items that shareholders and potential investors should be aware of.

Key Highlights from the Annual Meeting

• Election of Directors: All five director nominees were elected to serve one-year terms, expiring at the company’s 2027 Annual Meeting. The directors elected and their respective vote tallies are as follows:
  • Derek Small: 56,752,327 shares voted for; 2,485,600 against/abstained; 6,809,010 broker non-votes
  • Mark A. DiPaolo, Esq.: 50,072,119 shares for; 9,165,808 against/abstained; 6,809,010 broker non-votes
  • Sarah J. Schlesinger, M.D.: 53,509,479 shares for; 5,728,448 against/abstained; 6,809,010 broker non-votes
  • Pavel Raifeld: 58,880,013 shares for; 357,914 against/abstained; 6,809,010 broker non-votes
• Executive Compensation: Stockholders approved, on a non-binding advisory basis, Innoviva’s executive compensation package. The votes were:
  • 56,243,880 shares for
  • 2,836,001 shares against
  • 158,046 shares abstained
  • 6,809,010 broker non-votes
• Ratification of Independent Auditor: Deloitte & Touche LLP was ratified as the company’s independent registered public accounting firm for fiscal year 2026. The votes were:
  • 66,008,453 shares for
  • 16,574 shares against
  • 21,910 shares abstained
  • 0 broker non-votes
• Approval of 2026 Equity Incentive Plan: The company’s 2026 Equity Incentive Plan was approved by shareholders, with:
  • 55,435,111 shares for
  • 3,766,788 shares against
  • 36,028 shares abstained
  • 6,809,010 broker non-votes

Potential Price-Sensitive Developments

• Board Stability: The re-election of all director nominees, including CEO Pavel Raifeld, signals strong shareholder confidence in the current management and the company’s strategic direction.
• Executive Compensation Approval: Advisory approval of executive compensation indicates shareholder satisfaction with leadership performance and alignment of interests, potentially reducing the risk of activist intervention.
• Equity Incentive Plan Approval: The adoption of the 2026 Equity Incentive Plan allows Innoviva to grant future equity-based awards, which could impact earnings per share due to potential dilution but also serves as a tool to attract and retain top talent in a competitive sector.
• Continued Auditor Support: The overwhelming ratification of Deloitte & Touche LLP as independent auditors supports continuity in financial oversight and may reassure investors regarding financial transparency and governance.

Other Noteworthy Information

• Company Information: Innoviva, Inc. is based in Burlingame, California. Its current CEO is Pavel Raifeld. The company’s shares trade under the symbol INVA on the NASDAQ Global Select Market, with a par value of \$0.01 per share.
• Corporate Governance: The company is not classified as an emerging growth company, which means it complies with the full suite of SEC reporting and governance standards.

Conclusion

There were no surprises or contentious votes at Innoviva’s 2026 Annual Meeting, and all proposals were approved by comfortable margins. The approval of the new equity incentive plan and the smooth re-election of the board reinforce management’s stability and the company’s ongoing strategic initiatives. These developments may be viewed positively by the market, as they signal continued execution of Innoviva’s business plan and sustained shareholder support.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult a financial advisor before making investment decisions. The author and publisher are not responsible for any actions taken based on the information provided above.

View Innoviva, Inc. Historical chart here